Status:
COMPLETED
A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
Swiss Multiple Sclerosis Registry
Conditions:
Multiple Sclerosis
COVID-19 (Severe Coronavirus Disease 2019)
Eligibility:
All Genders
18+ years
Brief Summary
This nested project of the Swiss Multiple Sclerosis Cohort (SMSC) is to assess the severity of COVID-19 and the magnitude of antibody response after infection with Severe Acute Respiratory Syndrome Co...
Detailed Description
This nested project of the Swiss Multiple Sclerosis Cohort (SMSC) is to assess the severity of COVID-19 and the magnitude of antibody response after infection with Severe Acute Respiratory Syndrome Co...
Eligibility Criteria
Inclusion
- all patients in the Swiss Multiple Sclerosis Cohort (SMSC)
Exclusion
- Patients with Neuromyelitis optica and Radiologically Isolated Syndrome will be excluded
- Existence of a documented refusal of further use of health-related personal data and/or biological material
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 15 2023
Estimated Enrollment :
1181 Patients enrolled
Trial Details
Trial ID
NCT04760990
Start Date
February 1 2021
End Date
December 15 2023
Last Update
April 23 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Kantonsspital Aarau
Aarau, Switzerland, 5001
2
University Hospital Basel, Department of Neurology and Department of Biomedicine
Basel, Switzerland, 4031
3
Inselspital Bern
Bern, Switzerland, 3010
4
Hôpitaux Universitaires Genève
Geneva, Switzerland, 1205